Emergent BioSolutions (EBS) Tops Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Emergent BioSolutions Reports First Quarter 2016 Financial Results
May 5, 2016 4:18 PM EDTQ1 2016 financial performance in line with guidanceCDC notifies the Company of its intent to award a follow-on BioThrax procurement contract on October 1, 2016In transitioning to the follow-on contract, the Company is temporarily postponing its 2016 financial guidance until CDC confirms level of Q2 and Q3 BioThrax procurement
GAITHERSBURG, Md., May 05, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter ended March 31, 2016.
Q1 2016 FINANCIAL HIGHLIGHTS
Total revenues of $111.0 millionGAAP net income of $4.0 million, or $0.10 per diluted... More